Core Insights - Enlivex Therapeutics is raising $212 million in a private placement to become the first publicly traded U.S. company to adopt a blockchain-based prediction markets token, RAIN, as its main treasury reserve asset [1][3] - The RAIN token operates on the Arbitrum blockchain, enabling users to create and trade prediction markets on real-world events [1][2] - Enlivex plans to use the majority of the funds raised to purchase RAIN tokens, viewing the prediction markets space as a strategic growth area [3] Company Developments - Enlivex has a market cap of $22 million on Nasdaq and aims to integrate RAIN tokens into its treasury management strategy [3] - The company is continuing clinical trials for its lead drug candidate, Allocetra, which targets osteoarthritis, a condition affecting over 30 million Americans [4] - Matteo Renzi, former Prime Minister of Italy, is expected to join Enlivex's board following the completion of the deal on November 25 [5] Financial Aspects - The transaction is priced at $1 per share, representing an 11.5% premium over Enlivex's last trading price [5] - Last year, Enlivex's board approved the purchase of up to $1 million in Bitcoin as part of its cash-management strategy [5]

RT Brother Lyskey (@0xLyskey)you all want a buyback-and-burn mechanism on STRK, right?i want it too, and I voted in favor.vote link below. https://t.co/gn93KLPc8S ...

The WLFI team has issued a new governance proposal to enable a WLFI buyback and burn mechanismThe team has proposed taking 100% of their protocol-owned liquidity fees (on ETH, BSC & SOL) to buy WLFI & burn it https://t.co/ZGMF6hAMp1 ...